2026-03-07T03:30:25Z https://hama-med.repo.nii.ac.jp/oai

oai:hama-med.repo.nii.ac.jp:00003733 2023-08-02T05:24:03Z 1:11

Clinical significance of serum S100 calcium binding protein A4 in idiopathic pulmonary fibrosis S100A4 in IPF Akiyama, Norimichi Hozumi, Hironao Isayama, Takuya Okada, Jun Sugiura, Katsunori Yasui, Hideki Suzuki, Yuzo Kono, Masato Karayama, Masato Furuhashi, Kazuki Enomoto, Noriyuki Fujisawa, Tomoyuki Inui, Naoki Nakamura, Yutaro Suda, Takafumi "This is the peer reviewed version of the following article: ""Clinical significance of serum S100 calcium binding protein A4 in idiopathic pulmonary fibrosis, Respirology; 25(7): 743-749, 2020"", which has been published in final form at ""https://doi.org/10.1111/resp.13707"". This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions." Biomarker fibroblast idiopathic pulmonary fibrosis S100A4 Background and objective: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a poor prognosis. There are no established serum biomarkers for predicting the outcomes of IPF. S100 calcium binding protein A4 (S100A4) is considered a marker of fibroblasts; however, its clinical application remains to be investigated. We evaluated the clinical relevance of S100A4 in IPF patients. Methods: Serum S100A4 levels in 95 consecutive IPF patients and 50 healthy controls (HCs) were measured using enzyme-linked immunosorbent assay. S100A4 expression in lung tissues was determined using immunohistochemistry/immunofluorescence and its association with disease progression (defined as deterioration in lung function or death) and mortality was assessed using Kaplan?Meier method and Cox hazards analysis. Results: Serum S100A4 levels were undetectable in all HCs but were detectable in 26 (27.3%) of the 95 IPF patients (P<0.01). Immunostaining of lung tissues from IPF patients showed aggregation of numerous S100A4-expressing cells around the fibroblastic foci and mature fibrotic regions. IPF patients with higher serum S100A4 levels had a significantly worse prognosis than those with low serum levels (2-year cumulative survival rate, 41.7% vs. 77.0%, respectively, P<0.01). On multivariate analyses, baseline serum S100A4 levels (per 10 ng/mL increase) were independently associated with higher disease progression rate (odds ratio 1.06, P=0.01) and higher mortality (hazard ratio 1.18, P=0.03). Conclusions: S100A4 is a promising serum biomarker that may help predict disease progression/mortality. Our findings may help establish treatment strategies for IPF. John Wiley and Sons 2020-07 eng journal article AM http://hdl.handle.net/10271/00003859 https://hama-med.repo.nii.ac.jp/records/3733 31597225 10.1111/resp.13707 1323-7799 1440-1843 Respirology 25 7 743 749 https://hama-med.repo.nii.ac.jp/record/3733/files/Respirology-25-743.pdf application/pdf 1.2 MB 2021-07-01